FAAH and neoplasm: In non-malignant tissue, luminal FAAH immunoreactivity shows a lower intensity of staining than the tumour FAAH immunoreactivity, and neither non-malignant CB1 receptor immunoreactivity nor FAAH immunoreactivity is associated with disease severity or outcome14–17.